Mesenchymal stem cell exosomes: a promising delivery system for glioma therapy

Tianfei Ma,Gang Su,Qionghui Wu,Minghui Shen,Xinli Feng,Zhenchang Zhang
DOI: https://doi.org/10.1515/oncologie-2023-0482
2024-01-24
ONCOLOGIE
Abstract:Abstract Gliomas are particularly challenging due to their high invasiveness, frequent recurrence, and elevated mortality rates. Despite the availability of treatments like surgery, radiation, and chemotherapy, each of these methods faces significant limitations. This has led to a pressing demand for new strategies against gliomas. In this landscape, mesenchymal stem cells (MSCs) have shown significant potential in recent years. However, the application of MSCs in glioma therapy encounters various challenges. A significant advancement in this field is the utilization of exosomes (Exo), key secretions of MSCs. These exosomes not only carry the benefits inherent in MSCs but also exhibit unique physicochemical properties that make them effective drug carriers. Consequently, MSCs Exo is gaining recognition as a sophisticated drug delivery system, specifically designed for glioma treatment. The scope of MSCs Exo goes beyond being just an innovative drug delivery mechanism; it also shows potential as a standalone therapeutic option. This article aims to provide a detailed summary of the essential role of MSCs Exo in glioma progression and its growing importance as a drug delivery carrier in the fight against this formidable disease.
oncology
What problem does this paper attempt to address?
The paper primarily explores the potential application of mesenchymal stem cell-derived exosomes (MSCs Exo) in the treatment of glioma. Specifically, the paper addresses the following issues: 1. **Challenges in Glioma Treatment**: Glioma is highly invasive, prone to recurrence, and has a high mortality rate. Although current treatments include surgery, radiotherapy, and chemotherapy, each method has significant limitations. For example, it is difficult to completely remove the tumor, radiation can damage surrounding healthy brain tissue, and chemotherapy drugs struggle to cross the blood-brain barrier (BBB) and face resistance from tumor cells. 2. **Limitations of Mesenchymal Stem Cells**: While mesenchymal stem cells (MSCs) have the ability to home to tumor sites and inhibit tumor growth, they may transform into a phenotype that promotes tumor growth in the tumor microenvironment. This dual role complicates their application. 3. **Advantages of Exosomes as Drug Carriers**: Exosomes, as key secretions of mesenchymal stem cells, not only inherit the advantages of MSCs but also possess unique physicochemical properties, making them effective drug carriers. Exosomes can carry various biomolecules (such as proteins, RNA, DNA fragments, etc.) and migrate to target cells through multiple mechanisms, regulating their functional responses. 4. **Application of Exosomes in Glioma Treatment**: Studies have found that engineered exosomes can express molecules such as miRNA, mRNA, and siRNA, inhibiting the proliferation, invasion, and migration of glioma cells. Additionally, exosomes can overcome chemotherapy resistance and enhance the sensitivity of tumor cells to chemotherapy drugs, thereby improving treatment efficacy. In summary, the paper aims to explore the potential application of mesenchymal stem cell-derived exosomes in glioma treatment, particularly their advantages as a drug delivery system and the challenges they face.